A Review: Bilosomes as Nanocarriers

Bhawna      Sharma; Iti      Chauhan
Abstract

Liposomes and niosomes, two vesicular carriers that are prospective candidates for drug delivery, have been used in numerous formulations. New research in this area has led to the development of a ‘niosome-like’ colloidal carrier termed bilosomes. Bilosomes have been designed as prospective vesicular carriers to deliver targeted drugs via parenteral, transdermal, and oral routes.
These innovative vesicular systems, based on bile salts, have been discussed in detail in the current review. The review addresses the composition of bilosomes, their creation and characterization processes. Previous research on bilosomes has been compiled, along with their applications and advantages over more traditional nanocarriers such as liposomes and niosomes. It also emphasizes the utilization of bilosomes and their stability.
Graphical Abstract

[1]
Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine  2001; 19(20-22): 2965-74.
 [http://dx.doi.org/10.1016/S0264-410X(00)00537-5 ] [PMID:  11282208]

[2]
Stojančević M, Pavlović N, Goločorbin-Kon S, Mikov M. Application of bile acids in drug formulation and delivery. Front Life Sci  2013; 7(3-4): 112-22.
 [http://dx.doi.org/10.1080/21553769.2013.879925]

[3]
He H, Lu Y, Qi J, Zhu Q, Chen Z, Wu W. Adapting liposomes for oral drug delivery. Acta Pharm Sin B  2019; 9(1): 36-48.
 [http://dx.doi.org/10.1016/j.apsb.2018.06.005] [PMID:  30766776]

[4]
Aditya NP, Espinosa YG, Norton IT. Encapsulation systems for the delivery of hydrophilic nutraceuticals: Food application. Biotechnol Adv  2017; 35(4): 450-7.
 [http://dx.doi.org/10.1016/j.biotechadv.2017.03.012 ] [PMID:  28377276]

[5]
Ahmad R, Srivastava S, Ghosh S, Khare SK. Phytochemical delivery through nanocarriers: A review. Colloids Surf B Biointerfaces  2021; 197: 111389.
 [http://dx.doi.org/10.1016/j.colsurfb.2020.111389] [PMID:  33075659]

[6]
Van Tran V, Moon JY, Lee YC. Liposomes for delivery of antioxidants in cosmeceuticals: Challenges and development strategies. J Control Release  2019; 300: 114-40.
 [http://dx.doi.org/10.1016/j.jconrel.2019.03.003] [PMID:  30853528]

[7]
Ahmed S, Kassem MA, Sayed S. Bilosomes as promising nanovesicular carriers for improved transdermal delivery: construction, in vitro optimization, ex vivo permeation and in vivo evaluation. Int J Nanomedicine  2020; 15: 9783-98.
 [http://dx.doi.org/10.2147/IJN.S278688] [PMID:  33324052]

[8]
Shukla A, Mishra V, Kesharwani P. Bilosomes in the context of oral immunization: Development, challenges and opportunities. Drug Discov Today  2016; 21(6): 888-99.
 [http://dx.doi.org/10.1016/j.drudis.2016.03.013] [PMID:  27038539]

[9]
Chilkawar R, Nanjwade B, Nwaji M, Idris S, Mohamied A. Bilosomes based drug delivery system. J Chem Appl  2015; 2(5)

[10]
Pavlović N, Goločorbin-Kon S, Ðanić M, et al. Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles. Front Pharmacol  2018; 9: 1283.
 [http://dx.doi.org/10.3389/fphar.2018.01283] [PMID:  30467479]

[11]
Li J, Wang X, Zhang T, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci  2015; 10(2): 81-98.
 [http://dx.doi.org/10.1016/j.ajps.2014.09.004]

[12]
Vyas SP, Khar RK. Targeted & controlled drug delivery: novel carrier systems. CBS publishers & distributors 2004.

[13]
Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery—an overview. Acta Pharm Sin B  2011; 1(4): 208-19.
 [http://dx.doi.org/10.1016/j.apsb.2011.09.002]

[14]
Jiao J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv Drug Deliv Rev  2008; 60(15): 1663-73.
 [http://dx.doi.org/10.1016/j.addr.2008.09.002] [PMID:  18845195]

[15]
Shukla A, Singh B, Katare OP. Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano‐bilosomes. Br J Pharmacol  2011; 164(2b): 820-7.
 [http://dx.doi.org/10.1111/j.1476-5381.2011.01452.x ] [PMID:  21506959]

[16]
Wilkhu JS, McNeil SE, Anderson DE, Perrie Y. Characterization and optimization of bilosomes for oral vaccine delivery. J Drug Target  2013; 21(3): 291-9.
 [http://dx.doi.org/10.3109/1061186X.2012.747528] [PMID:  30952177]

[17]
Aburahma MH. Bile salts-containing vesicles: Promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines. Drug Deliv  2016; 23(6): 1847-67.
 [PMID:  25390191]

[18]
Mann JFS, Scales HE, Shakir E, et al. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods  2006; 38(2): 90-5.
 [http://dx.doi.org/10.1016/j.ymeth.2005.11.002] [PMID:  16414269]

[19]
Shukla A, Khatri K, Gupta PN, Goyal AK, Mehta A, Vyas SP. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharm Sci  2008; 11(1): 59-66.
 [http://dx.doi.org/10.18433/J3K01M] [PMID:  18445364]

[20]
Chen D, Wang X, Chen L, He J, Miao Z, Shen J. Novel liver-specific cholic acid-cytarabine conjugates with potent antitumor activities: Synthesis and biological characterization. Acta Pharmacol Sin  2011; 32(5): 664-72.
 [http://dx.doi.org/10.1038/aps.2011.7] [PMID:  21516131]

[21]
Chen Y, Lu Y, Chen J, et al. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm  2009; 376(1-2): 153-60.
 [http://dx.doi.org/10.1016/j.ijpharm.2009.04.022] [PMID:  19394416]

[22]
Niu M, Tan Y, Guan P, et al. Enhanced oral absorption of insulin-loaded liposomes containing bile salts: A mechanistic study. Int J Pharm  2014; 460(1-2): 119-30.
 [http://dx.doi.org/10.1016/j.ijpharm.2013.11.028] [PMID:  24275447]

[23]
Modi S, Anderson BD. Determination of drug release kinetics from nanoparticles: Overcoming pitfalls of the dynamic dialysis method. Mol Pharm  2013; 10(8): 3076-89.
 [http://dx.doi.org/10.1021/mp400154a] [PMID:  23758289]

[24]
Aziz DE, Abdelbary AA, Elassasy AI. Investigating superiority of novel bilosomes over niosomes in the transdermal delivery of diacerein: In vitro characterization, ex vivo permeation and in vivo skin deposition study. J Liposome Res  2019; 29(1): 73-85.
 [http://dx.doi.org/10.1080/08982104.2018.1430831 ] [PMID:  29355060]

[25]
Albash R, El-Nabarawi MA, Refai H, Abdelbary AA. Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. Int J Nanomedicine  2019; 14: 6555-74.
 [http://dx.doi.org/10.2147/IJN.S213613] [PMID:  31616143]

[26]
Waglewska E, Pucek-Kaczmarek A, Bazylińska U. Self-assembled bilosomes with stimuli-responsive properties as bioinspired dual-tunable nanoplatform for pH/temperature-triggered release of hybrid cargo. Colloids Surf B Biointerfaces  2022; 215: 112524.
 [http://dx.doi.org/10.1016/j.colsurfb.2022.112524] [PMID:  35500532]

[27]
Mohsen AM, Salama A, Kassem AA. Development of acetazolamide loaded bilosomes for improved ocular delivery: Preparation, characterization and in viv evaluation. J Drug Deliv Sci Technol  2020; 59: 101910.
 [http://dx.doi.org/10.1016/j.jddst.2020.101910]

[28]
Alhakamy NA, Caruso G, Al-Rabia MW, et al. Piceatannol-loaded bilosome-stabilized zein protein exhibits enhanced cytostatic and apoptotic activities in lung cancer cells. Pharmaceutics  2021; 13(5): 638.
 [http://dx.doi.org/10.3390/pharmaceutics13050638] [PMID:  33947103]

[29]
Abbas H, Gad HA, Khattab MA, Mansour M. The Tragedy of Alzheimer’s Disease: Towards better management via resveratrol-loaded oral bilosomes. Pharmaceutics  2021; 13(10): 1635.
 [http://dx.doi.org/10.3390/pharmaceutics13101635] [PMID:  34683928]

[30]
El Taweel MM, Aboul-Einien MH, Kassem MA, Elkasabgy NA. Intranasal zolmitriptan-loaded bilosomes with extended nasal mucociliary transit time for direct nose to brain delivery. Pharmaceutics  2021; 13(11): 1828.
 [http://dx.doi.org/10.3390/pharmaceutics13111828] [PMID:  34834242]

[31]
Abdelbary AA, Abd-Elsalam WH, Al-mahallawi AM. Fabrication of novel ultradeformable bilosomes for enhanced ocular delivery of terconazole: in vitro characterization, ex vivo permeation and in vivo safety assessment. Int J Pharm  2016; 513(1-2): 688-96.
 [http://dx.doi.org/10.1016/j.ijpharm.2016.10.006] [PMID:  27717916]

[32]
Alsaidan OA, Zafar A, Yasir M, Alzarea SI, Alqinyah M, Khalid M. Development of ciprofloxacin-loaded bilosomes in-situ gel for ocular delivery: Optimization, in-vitro characterization, ex-vivo permeation, and antimicrobial study. Gels  2022; 8(11): 687.
 [http://dx.doi.org/10.3390/gels8110687] [PMID:  36354595]

[33]
Nemr AA, El-Mahrouk GM, Badie HA. Hyaluronic acid-enriched bilosomes: An approach to enhance ocular delivery of agomelatine via D-optimal design: Formulation, in vitro characterization, and in vivo pharmacodynamic evaluation in rabbits. Drug Deliv  2022; 29(1): 2343-56.
 [http://dx.doi.org/10.1080/10717544.2022.2100513 ] [PMID:  35869684]

[34]
Janga KY, Tatke A, Balguri SP, et al. Ion-sensitive in situ hydrogels of natamycin bilosomes for enhanced and prolonged ocular pharmacotherapy: In vitro permeability, cytotoxicity and in vivo evaluation. Artif Cells Nanomed Biotechnol  2018; 46(S1): 1039-50.

[35]
Al-mahallawi AM, Abdelbary AA, Aburahma MH. Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam. Int J Pharm  2015; 485(1-2): 329-40.
 [http://dx.doi.org/10.1016/j.ijpharm.2015.03.033] [PMID:  25796122]

[36]
Khalil RM, Abdelbary A, Kocova El-Arini S, Basha M, El-Hashemy HA. Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization. J Liposome Res  2019; 29(2): 171-82.
 [http://dx.doi.org/10.1080/08982104.2018.1524482 ] [PMID:  30221568]

[37]
Mishra N, Shailja T, Bhuvaneshwar V. Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B. J Drug Target  2010; 19: 67-78.

[38]
Moses OO, Amit K, Zhengrong C. Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses. Expert Rev Vaccines  2011; 9: 1095-107.

[39]
Shalaby WSW. Development of oral vaccines to stimulate mucosal and systemic immunity: barriers and novel strategies. Clin Immunol Immunopathol  1995; 74(2): 127-34.
 [http://dx.doi.org/10.1006/clin.1995.1019] [PMID:  7828366]

[40]
Rajput T, Chauhan MK. Bilosome: A bile salt based novel carrier system gaining interest in pharmaceutical research. J Drug Deliv Ther  2017; 7(5): 4-16.
 [http://dx.doi.org/10.22270/jddt.v7i5.1479]

[41]
Preparation of non-ionic surfactant vesicles and variants. WO Patent 2018011553A2, 2018.

[42]
David E. Methods for preparing vesicles and formulations produced therefrom, international publication. WO Patent 2011005769A1, 2017.

[43]
Diaz-Mitoma F. Compositions and methods for treating influenza. US Patent, US9603920B2, 2017.

[44]
Suvarna V, Mallya R, Deshmukh K, Sawant B, Khan TA, Omri A. Novel vesicular bilosomal delivery systems for dermal/transdermal applications. Curr Drug Deliv 2023.
 [PMID:  37424346]

[45]
Karunakaran B, Gupta R, Patel P, et al. Emerging trends in lipid-based vaccine delivery: A special focus on developmental strategies, fabrication methods, and applications. Vaccines  2023; 11(3): 661.
 [http://dx.doi.org/10.3390/vaccines11030661] [PMID:  36992244]

[46]
Elsheikh MA, Elnaggar YSR, Abdallah OY. Rationale employment of cell culture versus conventional techniques in pharmaceutical appraisal of nanocarriers. J Control Release  2014; 194: 92-102.
 [http://dx.doi.org/10.1016/j.jconrel.2014.08.019] [PMID:  25194779]
Cite As
Current Nanomedicine

A Review: Bilosomes as Nanocarriers

Abstract

Graphical Abstract
